Add to Calendar 3/27/2019 8:15:00 AM 3/28/2019 2:30:00 PM 2019 Annual Meeting: State of Possible Conference
This year’s Annual Meeting is now the State of Possible Conference where we'll celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks, inspiring and engaging content in the style of a TED Talk. We'll also have a networking reception, the State of Possible Celebration, immediately following Day 1 of the conference, where we'll have great food, drinks, a DJ. Attendees will also have access to the exhibits at the Museum of Science. Join us as we celebrate the State of Possible!
 

If you haven’t attended our Annual Meeting before, it is the premier east coast life sciences conference and this year’s event is better than ever. With speakers like Katrine Bosley, John Maraganore, Jeremy Levin, George Church, and more, we have some of the brightest names in biotech talking about the issues impacting our industry. See our incredible lineup of speakers and topics below. Online registration closes at noon on Tuesday, March 26th. Walk-in registrations will be available on-site. 

 Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
CEO, Concerto HealthAI
Jeff Elton, Ph.D., is CEO of Concerto HealthAI, a rapidly growing Precision Oncology company with facilities in New York, Philadelphia, Los Altos, and Bangalore that recently moved its headquarters to Boston. Concerto HealthAI is a partner with the American Society of Clinical Oncology’s CancerLinQ program, working with that group and U.S. FDA to advance the use of real world data for pre- and post-approval regulatory submissions, outcomes studies, and value-based care. Previously, he was Managing Director, Accenture Strategy & Predictive Health Intelligence, global COO of Novartis’ Institutes for BioMedical Research and a McKinsey partner in Pharmaceuticals & Medical Products. Dr. Elton co-authored, “Healthcare Disrupted: Next Generation Business Models and Strategies” in 2016, creating an industry roadmap for AI, advanced analytics, real-world data and digital medical solutions.

Brought to you by